Day 1 :
Managing Director, Elite Derma Care Center, Saudi Arabia
Time : 09:00AM-10:00AM
Dr. Saad Sami Al Sogair is a Board certified Dermatologist and faculty member of the American Aesthetic Association. He is also an active speaking member of multiple international Aesthetic and Anti-Aging societies and academies. Including the Saudi Society of Dermatology and Dermatologic Surgery, the Swiss Academy of Cosmetic Dermatology & Aesthetic Medicine, the American Academy of Aesthetic Medicine and the American Academy of Anti-Aging Medicine. Dr. Sogair has numerous published articles translated into many languages including Italian and Portuguese. His findings in Aesthetic Dermatology were described by Reuters as “breakthrough.”
Skin is the largest and the most visible organ of the human body. Aged skin is biologically characterized by the flattening of the dermal-epidermal junction, general atrophy of the extracellular matrix (ECM) and disorganized and reduced collagen and elastin. Skin aging can be delayed by external application to suppress production of free radicals or to neutralize excess free radicals. Methylene blue is a century-old drug has potent antibiotic and antioxidant properties and has the ability to suppress production of superoxide radicals. It acts as an alternative receptor of xanthine oxide electrons and has received increased attention due to its usefulness in treating mitochondrial dysfunction. MB at nanomolar concentration has been found to be potent in scavenging free radicals and stimulate cell proliferation in both young and old dermal fibroblasts. MB treatment on 3D reconstructed skin models provides strong evidence of its potential for improving skin viability, increasing skin hydration and thickness, promoting skin elastin and collagen synthesis, and protecting the skin matrix through the inhibition of enzymatic degradation by MMP. Altogether, this presentation suggests that MB can be a promising agent for use in anti-aging cosmetics.
Dorrington Medical Associates, Houston, Texas, USA
Time : 10:00AM-11:00AM
Andrea Merino-Ruisanchez is a physician from the Universidad Popular Autonoma del Estado de Puebla (UPAEP) in Mexico. Following a clinical Psychology diplomate, she developed a keen interest in dermatology. She has presented internationally data on the prevalence of dermatologic and ophthalmic manifestations in systemic lupus erythematous. She is certified in “Good Clinical Practices” by the NIDA Clinical trials network.
Basosquamous cell carcinoma (BSC) is a rare, and potentially aggressive, skin neoplasm with features of both basal cell carcinoma (BCC), and squamous cell carcinoma (SCC) with a transition zone and a non-specific clinical presentation. We recently saw a 57-year-old gentleman who presented ulcerated BSC on the right shoulder reaching the acromion with a polymicrobial infection. Microscopical analysis showed a transition zone between BCC and SCC. A Periodic acid-Shiff-Fungus special stain was negative for fungal organisms. BSC represents less that 5% of all non-melanoma skin tumors. The incidence is less than 2% but the true incidence may be higher due to rarity and difficulty of diagnosis. This neoplasm is most commonly found on head and neck on 82-97% of cases. In 2005, the World Health Organization defined BSC as a term used to describe BCC that is associated with squamous differentiation. Prompt recognition of BSC is important in order to aggressively treat and predict the prognosis.